Serine palmitoyltransferase 1 (SPT1), encoded by the SPTLC1 gene, is a key catalytic subunit of the serine palmitoyltransferase (SPT) complex, the rate-limiting enzyme in de novo sphingolipid biosynthesis. Located on chromosome 9q22.31, SPTLC1 encodes a 629-amino acid protein that forms the functional core of the SPT heteromeric complex. This enzyme catalyzes the initial and critical step of sphingoid base synthesis by condensing the amino acid L-serine with palmitoyl-CoA (a long-chain fatty acyl-CoA), forming 3-ketosphinganine. SPT1 is predominantly expressed in the nervous system, liver, and kidney, with particularly high abundance in neurons and oligodendrocytes. The protein localizes to the endoplasmic reticulum (ER) membrane, where it functions as part of a multi-subunit complex essential for maintaining cellular sphingolipid homeostasis.
Function and Biology
The SPT complex functions as a membrane-associated enzymatic machinery requiring multiple subunits for proper assembly and catalytic activity. SPT1 provides the core catalytic domain containing the pyridoxal-5'-phosphate (PLP) cofactor binding site, which is essential for the condensation reaction between serine and palmitoyl-CoA. The enzyme works in concert with SPT2 (SPTLC2), which acts as a regulatory subunit, and small subunits SPTSSA (also called SAC1) and SPTSSP2 (also called SAC2), which modulate enzyme specificity and stability.
...
Serine Palmitoyltransferase 1 Protein
Overview
Serine palmitoyltransferase 1 (SPT1), encoded by the SPTLC1 gene, is a key catalytic subunit of the serine palmitoyltransferase (SPT) complex, the rate-limiting enzyme in de novo sphingolipid biosynthesis. Located on chromosome 9q22.31, SPTLC1 encodes a 629-amino acid protein that forms the functional core of the SPT heteromeric complex. This enzyme catalyzes the initial and critical step of sphingoid base synthesis by condensing the amino acid L-serine with palmitoyl-CoA (a long-chain fatty acyl-CoA), forming 3-ketosphinganine. SPT1 is predominantly expressed in the nervous system, liver, and kidney, with particularly high abundance in neurons and oligodendrocytes. The protein localizes to the endoplasmic reticulum (ER) membrane, where it functions as part of a multi-subunit complex essential for maintaining cellular sphingolipid homeostasis.
Function and Biology
The SPT complex functions as a membrane-associated enzymatic machinery requiring multiple subunits for proper assembly and catalytic activity. SPT1 provides the core catalytic domain containing the pyridoxal-5'-phosphate (PLP) cofactor binding site, which is essential for the condensation reaction between serine and palmitoyl-CoA. The enzyme works in concert with SPT2 (SPTLC2), which acts as a regulatory subunit, and small subunits SPTSSA (also called SAC1) and SPTSSP2 (also called SAC2), which modulate enzyme specificity and stability.
Sphingolipids generated through SPT activity are fundamental structural and signaling components of biological membranes, particularly abundant in myelin sheaths and neuronal plasma membranes. These lipids comprise approximately 10-15% of total brain lipids and are essential for myelin formation, membrane organization, synaptic transmission, and cellular signaling. Beyond structural roles, sphingoid bases and their phosphorylated derivatives (sphingoid-1-phosphate) function as critical signaling molecules regulating cell survival, apoptosis, and immune responses. The de novo pathway controlled by SPT1 serves as the primary source of sphingoid bases in most tissues, though alternative salvage pathways can recycle existing sphingosine.
Role in Neurodegeneration
Mutations in SPTLC1 cause hereditary sensory and autonomic neuropathy type 1 (HSAN1), a dominantly inherited neurodegenerative disorder characterized by progressive distal sensory neuron loss and autonomic dysfunction. Most pathogenic SPTLC1 mutations are heterozygous missense variants that alter amino acid residues in or near the active site or regulatory regions, paradoxically causing gain-of-function effects. These mutations broaden the substrate specificity of the SPT complex, enabling it to catalyze the condensation of serine with atypical fatty acids, including deoxysphingolipids (deoxydhCer and deoxyHS1P) with 1-deoxysphinganine backbones. Accumulation of these toxic deoxysphingolipids in neurons appears directly neurotoxic, causing ER stress, mitochondrial dysfunction, and triggering apoptotic pathways.
The selective vulnerability of sensory neurons to SPTLC1 mutations remains incompletely understood but may relate to their exceptional metabolic demands and dependence on proper sphingolipid metabolism for axonal integrity and long-distance nutrient transport. Deoxysphingolipids disrupt normal membrane properties and compromise cellular homeostasis mechanisms in ways that preferentially affect neurons.
Molecular Mechanisms
Pathogenic SPTLC1 mutations alter enzyme specificity through structural changes affecting substrate selection. The protein contains key structural motifs including transmembrane domains that anchor it to the ER, and the catalytic site rich in conserved residues from the PLP-dependent transferase superfamily. Wild-type SPT complexes maintain tight substrate specificity, preferentially condensing serine with palmitoyl-CoA. Disease-associated mutations reduce this selectivity, permitting condensation with myristoyl-CoA and other shorter-chain fatty acyl-CoAs, generating aberrant deoxysphingoid bases. These modified lipids bypass normal quality control mechanisms and become incorporated into cellular membranes, causing lipotoxicity and neuronal death.
Clinical and Research Significance
SPTLC1 mutations represent one of the most common genetic causes of hereditary sensory neuropathy, accounting for approximately 40-50% of HSAN1 cases. Understanding SPT1 dysfunction has illuminated how gain-of-function mutations can drive neurodegeneration and has revealed the critical importance of sphingolipid composition to neuronal survival. Current research investigates SPT1 inhibitors as potential therapeutic strategies for HSAN1, with compounds targeting the enzyme to normalize substrate specificity showing promising results in preclinical studies.